-
Adverse events: Cornerstone for safer pathways?
August 14, 2023Learning points from morbidity and mortality Adverse events can positively transform new approaches in patient management. How? By applying...
0 -
AI opportunities in GU Cancers
November 12, 2022Looking to the future, Prof. Arnulf Stenzl (DE), Prof. Alberto Briganti (IT) and Dr. Bob Schijvenaars (NL) chaired the...
-
New trial results for PEACE-1, OpeRa, and adjuvant therapies in high-risk RCC
November 12, 2022A selection of new trial results were shared and discussed in Plenary Session 5 on day three of EMUC22....
-
Diagnosing PCa – what’s the best option?
November 11, 2022The objective of the 14th European Multidisciplinary Congress on Urological Cancers is to work together to achieve the best...
-
The parallels to mountaineering are everywhere, even in urology
September 27, 2022Vital updates on major trials, emerging technologies, and pioneering techniques will be featured during the 14th European Multidisciplinary Congress...
-
Protect yourself: Fake EMUC22 websites and scam emails
September 8, 2022Planning to attend EMUC22? Protect yourself against registration and hotel booking scams. Here’s how: Register via EMUC22’s official website...
-
Recap of EMUC21: The take-home messages
November 30, 2021Being an event with a multidisciplinary nature, the take-home messages of the 13th European Multidisciplinary Congress on Urological Cancers...
-
Another EMUC21 day, another round of best poster award winners
November 28, 2021After three experts from three different fields had won the Best Poster Award – Prostate Cancer on the third...
-
Personalised approaches to treating GU cancers
November 27, 2021Personalised approaches such as the use of circulating tumour DNA (ctDNA) biomarkers and genetic testing is the way to...
-
EMUC21 shines spotlight on best poster winners
November 27, 2021Demonstrating the multidisciplinary nature of the congress, an oncologist, a radiotherapist, and a urologist each received a Best Poster...
